Humacyte, Inc.
NASDAQ Global SelectTotal Valuation
Humacyte, Inc. carries a market capitalization of 1.08M, placing it among publicly traded companies globally. Its enterprise value stands at -11.06M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.08M |
| Enterprise Value | -11.06M |
Share Statistics
Humacyte, Inc. currently has 277.80M shares outstanding.
| Shares Outstanding | 277.80M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.09 |
| P/TBV Ratio | 0.09 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 68.06 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Humacyte, Inc. maintains a current ratio of 6.21, meaning it holds 6.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 211.70, indicating elevated leverage, while an interest coverage ratio of -10.09 demonstrates limited ability to service its debt obligations.
| Current Ratio | 6.21 |
| Quick Ratio | 5.37 |
| Debt / Equity | 211.70 |
| Debt / EBITDA | -0.64 |
| Interest Coverage | -10.09 |
Financial Efficiency
| Return on Equity (ROE) | -547.87 |
| Return on Assets (ROA) | -69.87 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.40 |
Stock Price Statistics
Humacyte, Inc.'s stock has declined approximately -99.65035% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.09.
| Beta (5Y) | N/A |
| 52-Week Price Change | -99.65035% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.09 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -103.93M, while operating income came in at -111.16M.
| Revenue | 2.12M |
| Gross Profit | -10.49M |
| Operating Income | -111.16M |
| Pretax Income | -96.73M |
| Net Income | -96.73M |
| EBITDA | -103.93M |
| EBIT | -111.16M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Humacyte, Inc. holds 79.90M in cash and equivalents against 66.18M in total debt, resulting in a net debt position of -43.58M. Total book value stands at 31.26M, with working capital of 77.84M providing operational flexibility.
| Cash & Cash Equivalents | 79.90M |
| Total Debt | 66.18M |
| Net Debt | -43.58M |
| Equity (Book Value) | 31.26M |
| Book Value Per Share | 0.11 |
| Working Capital | 77.84M |
Cash Flow
Humacyte, Inc. produced -97.19M in operating cash flow over the past twelve months.
| Operating Cash Flow | -97.19M |
| Capital Expenditures | -367,000.00 |
| Free Cash Flow | -97.56M |
| FCF Per Share | N/A |
Margins
Humacyte, Inc. operates with a gross margin of -494.58, reflecting its pricing power and cost economics. The operating margin of -5,240.78 and net profit margin of -4,560.82 provide insight into operational efficiency.
| Gross Margin | -494.58 |
| Operating Margin | -5,240.78 |
| Pretax Margin | -4,560.82 |
| Profit Margin | -4,560.82 |
| EBITDA Margin | -4,899.95 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -3,353.42 |
| FCF Yield | N/A |
Scores
Humacyte, Inc. posts an Altman Z-Score of -9.87, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -9.87 |